Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2025 08:00 ET | Source: Daxor Corporation

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment Oak Ridge, TN, Feb. 14, 2025 (GLOBE...
April 08, 2024 11:15 ET | Source: Imbria Pharmaceuticals Inc.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
July 07, 2020 08:30 ET | Source: ARCA biopharma, Inc.

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Integrin A5 may be a new target for intervening in the cell infectious processFindings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving...
March 28, 2018 02:00 ET | Source: BioSig Technologies, Inc.

BioSig Announces Submission of FDA 510(k) Application for PURE EP™ System

SANTA MONICA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA)...
February 21, 2017 08:00 ET | Source: BioSig Technologies, Inc.

JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016

Minneapolis, MN, Feb. 21, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to...
February 19, 2017 20:00 ET | Source: BioSig Technologies, Inc.

JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016

MINNEAPOLIS, Feb. 20, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an...
January 11, 2017 08:00 ET | Source: BioSig Technologies, Inc.

BioSig Technologies’ PURE EP System Featured in The Journal of the American College of Cardiology: Clinical Electrophysiology

Minneapolis, MN, Jan. 11, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary technology platform designed to improve the $4 billion...